Biote Corp. (BTMD) Stock
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Ownership
About Biote Corp.
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.
Biote Corp. is led by CEO Bret Christensen, employs 217 people, headquartered in US, publicly traded since 2021.
Biote Corp. (BTMD) stock trades at $1.07 with a market capitalization of $47.20M. The stock is valued at a price-to-earnings (P/E) ratio of 6.61, a negative price-to-book of -0.48, reflecting negative shareholders' equity, price-to-sales of 0.27. Over the past 52 weeks the stock has ranged between $1.00 and $3.26, and currently trades 67.2% below its 52-week high.
On profitability, Biote Corp. generates a return on equity (ROE) of -9.25% (not meaningful, as shareholders' equity is negative), return on capital employed of 57.14%, an operating margin of 20.31%, a net profit margin of 3.19%.
Official website: biote.com
Biote Corp. by the numbers, 2019–2025
Between 2019 and 2025 Biote Corp. reported revenue of $110.0M rising to $192.0M, a change of +74.5% across 7 years. Compounded, revenue has grown 10.4% a year over five years, 5.2% over three, -2.5% over the last twelve months. Net profit rose to $27.0M.
Operating margin went from 21.4% in 2019 to 18.5% in 2025, a fall of 2.9 percentage points. The most recent net margin is 3.19%. On a trailing twelve-month basis to Jun '26, revenue is $183.0M and net profit $5.0M.
Borrowings rose from $47.0M to $110.0M, cash from operations was $35.0M in the latest year, positive in 6 of the last 7.
Return on equity has averaged 153.7% over five years, and was -45.8% in the most recent year.
The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.
Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.
Biote Corp. (BTMD) — frequently asked questions
What is Biote Corp. (BTMD) stock price today?
Biote Corp. (BTMD) is currently trading at $1.07, down 1.83% today.
What is BTMD P/E ratio?
Biote Corp.'s P/E ratio is 6.61. This is below the typical market average of roughly 18-22x. A low P/E can reflect a lower valuation, slower expected growth, or both.
What is BTMD return on equity (ROE)?
Biote Corp.'s return on equity (ROE) is -9.25%. ROE measures net income relative to shareholders' equity. Shareholders' equity is negative, so ROE is not a meaningful measure for this company.
What is Biote Corp.'s market cap?
Biote Corp. has a market capitalization of $47.20M.
Does BTMD pay a dividend?
Biote Corp. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does BTMD carry?
Biote Corp. has a debt-to-equity ratio of -1.96. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is BTMD's profit margin?
Biote Corp. reports a net profit margin of 3.19% — the share of revenue left after every cost, including tax and interest.
What sector is BTMD in?
Biote Corp. is classified under Healthcare, in the Medical - Care Facilities industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is BTMD listed on?
Biote Corp. trades on NASDAQ under the ticker BTMD.
What is BTMD's 52-week range?
Over the last year Biote Corp. has traded between $1.00 and $3.26.
Related Healthcare Stocks
Popular Stocks
Screens BTMD currently matches
On the figures above, Biote Corp. passes the filters for 2 of our ready-made screens, among them Penny Stocks, Nano Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.